The Digital Medicine Society (DiME) launched a new set of FDA-aligned digital measures to standardize how outcomes are tracked in pediatric rare disease trials. The framework aims to make trials faster and more efficient, giving researchers and drugmakers a practical roadmap for developing new therapies for children who often have no effective treatment options.
Cleveland Clinic is expanding its use of Dyania Health’s AI platform across the health system to speed up clinical trial recruitment. The system quickly scans patient records to identify eligible participants, aiming to give more patients access to trials and speed up development timelines for new therapies.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Pluto Health launched an AI-driven digital hub that unifies fragmented health data, provides personalized care navigation and integrates clinical research opportunities to help close primary care access gaps. The platform aims to improve care coordination and make research participation more accessible, especially for patients without insurance or a regular primary care provider.
The letter is an extraordinary rebuke of the Trump administration’s actions against the NIH, which include: terminating hundreds of grants funding scientific and biomedical research; firing more than 1,000 employees this year; and moving to end billions in funds to partner institutions overseas.
As demand for trial sites increases, more investigators are overburdened or experiencing burnout. What can the industry do to help?
Modern trial designs, digital solutions and a deeper understanding of patient realities are helping to open research to more people, including women and others who have historically been underrepresented.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Understanding how site augmentation services could be leveraged to overcome challenges is not the responsibility of one entity. The most creative and effective solutions arise from collaboration among all stakeholders — sponsors, CROs, service providers, and research sites.
This week, longtime healthcare veterans Amy Abernethy and Brad Hirsch teamed up to launch Highlander Health — a Dallas-based startup focused on accelerating clinical evidence generation.
A direct-to-patient model for observational research will ease the participation burden, better incorporate the patient voice, and empower individuals to take control of their health – all while meeting the growing demands for robust evidence in developing new drugs and therapeutics.
This not only enhances the quality of care and patient satisfaction but also optimizes operational efficiency.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Given our questionable track record of driving consistent progress, it’s important that we create a roadmap to optimize the success for this exciting moment.
Enzo BioChem’s sale of its clinical lab business to Labcorp is the culmination of a monthslong strategic review. Meanwhile, diagnostics and lab testing giant Labcorp is in the middle of its own corporate shakeup as it readies its clinical trials business for a spinoff as a standalone, publicly traded company.
Paradigm, a new startup co-incubated by ARCH Venture Partners and General Catalyst, recently launched with $203 million in Series A funding. The company is focused on improving equitable access to trials by creating a less fragmented and more efficient clinical research ecosystem.
Crescendo Health recently launched with a $3.4 million initial investment. The startup provides clinical researchers with software tools that make it easier to gather study participants' longitudinal health data.
The goal of implementing artificial intelligence and machine learning in clinical research is not to replace humans with digital tools but to increase their productivity.